Anumana Partners With the American College of Cardiology

Anumana is joining the American College of Cardiology’s (ACC) Innovation Program to accelerate the detection and treatment of cardiovascular disease.

The collaboration combines Anumana’s expertise in developing AI-based Software-as-a-Medical Device (SaMD) with ACC’s mission to support and transform patient care, bridging the gap between cutting-edge research and the challenges clinicians face in detecting low ejection fraction (LEF). Anumana’s U.S. Food and Drug Administratioin-cleared ECG-AI LEF algorithm—which has been included in the CMS 2025 OPPS final rule (effective this month)—analyzes standard 12-lead electrocardiogram data to identify LEF, a potential early asymptomatic key indicator of heart failure. The ACC Innovation Program and its network of cardiology experts will help Anumana optimize the integration of this algorithm into clinical workflows.

“Joining the ACC Innovation Program provides a unique opportunity to bring Anumana’s AI technology into closer alignment with clinical practice,” Anumana CEO Maulik Nanavaty said. “Collaborating with ACC’s industry experts and physicians will help us to further our commitment to developing evidence-based, AI solutions that fit into everyday practice, ultimately improving patient outcomes and addressing the evolving needs of cardiology care.”

The ACC Innovation Program is driving the digital transformation of cardiovascular care by combining research, engagement, and thought leadership. Working with industry experts and academic institutions, the program advances initiatives that improve patient outcomes. ACC aims to search for, aid, and promote the development of technologies that will enable its members to advance patient care.

“Cardiovascular disease remains the leading cause of death worldwide, underscoring the need for innovative solutions that will help physicians detect and manage heart conditions earlier,” ACC Chief Innovation Officer Ami Bhatt stated. “Anumana’s technology offers an opportunity to create a scalable and equitable approach to early disease detection. Together, we’re paving the way for more proactive heart failure management that can improve heart health and deliver tangible benefits to patients.”

Anumana is an artificial intelligence (AI)-driven health technology company leveraging AI and translational science to unlock the heart’s electrical language. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s SaMD ECG-AI solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. Anumana’s 12-lead algorithm, ECG-AI LEF, is now available in the United States.

The American College of Cardiology (ACC) aims to transform cardiovascular care and improve heart health. As the preeminent source of professional medical education for cardiovascular care teams since 1949, ACC credentials cardiovascular professionals in more than 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its family of JACC Journals, NCDR registries, ACC accreditation services, global network of member sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes.